# A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

> **NCT05801029** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 60 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT05801029
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-18
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05801029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05801029, "A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05801029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*